Biofrontera AG pivotal Phase III data demonstrate significant efficacy and excellent safety for BF-200 ALA treatment of superficial skin cancer

Biofrontera AG (FSE: B8F), the specialist for sun-induced skin cancer, presented data from three pivotal Phase III trials for its lead drug candidate BF-200 ALA at the 14th Annual South Beach...